Marijuana use for medicinal purposes is legal in 29 U.S. states, yet the UK government has said it has no plans to legalise the drug. Joining Good Morning Britain to give their opinion on the ongoing debate is Bobby George, former professional darts player, and Linda Robson, Loose Women panellist.
Tag Archives: England
Several British lawmakers lent their support to a cannabis tea party on the lawns outside parliament on Tuesday, protesting against legislation that criminalizes use of the drug for medical purposes.
As countries across the world look to decriminalise cannabis, Jim Connolly asks whether it’s time to change the law on cannabis in the UK.
Oxford University, one of the oldest and most prestigious universities in the world, recently announced that it is launching a program to research the therapeutic benefits of cannabinoids in the treatment of cancer, inflammatory disease and pain.
OXFORD, England, March 15, 2017 /Weed Wire/ — Oxford University (“Oxford”) and Kingsley Capital Partners (“Kingsley”) today announce the launch of a pioneering research programme to investigate the role of cannabinoids in biology and medicine.
On April 20, 2016, Trollstation, a web-comedy group, released “420 London High Hotbox,” a video that documents the group boarding a pod on the Coca-Cola London Eye, the largest cantilevered observation wheel in the world, and hotboxing it to film a music video during the wheel’s 30-minute rotation.
As the Western Hemisphere heads into fall, a strange thing is starting to happen across the pond. Not one but several companies who manufacture and distribute cannabinoid-processed end products are looking to European expansion.
While it is a far cry from rolling back prohibition altogether, the legalization wave appears to be crashing upon the beaches of the British Isles this summer. As of July 31, 2015, the branded “Charlotte’s Web” CBD oil went on sale in England after it was legalized last month.
LONDON, Oct 8 (Reuters) – A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company’s home market.